Scrip
Sepracor looks to benefit its new owners
13 November 2009
Ian Haydock
Please Login to read the full article.
13 November 2009
Ian Haydock
Dainippon Sumitomo Pharma's new US subsidiary, Sepracor, expects to be debt free by the end of this year and is forecasting full-year non-GAAP revenues of $1.23-1.28 billion, compared with $1.29 billion in 2008.
The guidance for fully diluted earnings per share was raised earlier this year...
Please Login to read the full article.
RELATED CONTENT
ANALYSIS
Other Informa Analysis
COMMENT
Other Informa Comment
EVENTS
17 March 2010
Berlin, Germany
17 March 2010
Berlin, Germany
22 March 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
